The past two decades have underscored the global vulnerability to emerging RNA viruses. The rapid evolution of viral polymerases, combined with limited therapeutic options, has driven the need for broad‑acting antivirals that can be deployed quickly against novel pathogens. ADN‑388, discovered by in 2023, represents a paradigm shift: a single molecule capable of inhibiting a conserved enzymatic pocket across multiple viral families.
: It is engineered to minimize the recruitment of -arrestin. In traditional drugs, ADN-388